Tryptamine Therapeutics Limited (ASX:TYP)

Market Cap	41.73M
Revenue (ttm)	1.33M
Net Income (ttm)	-7.37M
Shares Out	1.44B
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,408,658
Average Volume	1,217,227
Open	0.0290
Previous Close	0.0290
Day's Range	0.0290 - 0.0290
52-Week Range	0.0170 - 0.0570
Beta	n/a
RSI	39.91
Earnings Date	Sep 30, 2025

About Tryptamine Therapeutics

Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing synthetic psilocybin-related molecules in Australia, Canada, Switzerland, and the United States. The company’s lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin, c...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: TYP